Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.
Eli Lilly will ‘build new way of doing science’ in UK amid £297m pledge to government – Pharmaceutical Technology
Ramesh Durvasula leading the opening keynote at the TechBio UK 2024 conference in London. Credit: Jenna Philpott/GlobalData. An Eli Lilly executive has said the company